

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In regard to the application of: Nissim DARVISH, et al.

Serial No: 09/980,908

Group Art Unit: 3763

Filed: December 4, 2001

Examiner: To be assigned

For: DRUG DELIVERY DEVICE

INFORMATION DISCLOSURE STATEMENT

RECEIVED
APR 23 2002
TECHNOLOGY CENTER R3700

Hon. Commissioner of Patents and Trademarks

Washington, DC 20231

Sir:

Applicants respectfully direct the attention of the Examiner to art cited with respect to PCT/IL00/00319 of which the current application is a US national application under 35 USC section 371.

The Examiner is respectfully requested to review and consider this art, in accordance with MPEP 2001.06, MPEP 1893.03(e) and MPEP 1893.03(g) and to indicate in the first office action that he has considered this art. Additionally, the Examiner is respectfully requested to cite those prior art publications mentioned in this application which the Examiner considers to be material or relevant to the present claims.

Further, in order to comply with discretionary regulations 37 CFR 1.97 and 1.98, attached is Form PTO-1449 listing the cited art. Also attached are copies¹ of the art. This art contains information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent. Items 1-2 and 12 were cited on the PCT International Search Report. Copies of these items are not attached as they are available in the national stage file.

¹ To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the national stage file. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached, it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such an equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited then none is known to the undersigned.


Applicants wish to bring to the attention of the Examiner that items 14, 16 and 21 were filed between the earliest priority date (June 4, 1999) and the international filing date of the present application (June 4, 2000). Also, items 31-32, 36 and 39 were published between the earliest priority date (June 4, 1999) and the international filing date of the present application (June 4, 2000).

In accordance with MPEP Section 609 it is requested that each document cited (including any mentioned in Applicant's specification which is not repeated on the attached PTO-1449 form) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on the PTO-1449 form, so that it will appear on the face of the patent issuing on the present application, even if the Examiner does not consider it sufficiently pertinent to use in a rejection, or otherwise does not believe that the guidelines for citation have been fully complied with.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56 as an Examiner might consider any cited document important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37CFR 1.104(a), and in the course of such search will review for relevance every document cited on the attached form.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,
Nissim DARVISH, et al.



Maier FENSTER,
Registration No. 41,016

April 15, 2002
William H. Dippert, Esq.
Cowan, Liebowitz and Latman, P.C.
1133 Avenue of the Americas
New York, NY 10036-6799
Tel: (212) 790-9200

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY DOCKET NO.

015/02481

SERIAL NO.

09/980,908

Nissim DARVISH, et al.

FILING

December 4, 2001

GROUP

3763

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
1	5,087,243	11 Feb '92	AVITALL, B.			
2	5,634,899	3 Jun '97	SHAPLAND, J. E. et al.			
3	5,501,662	26 Mar '96	HOFMANN, G. A.			
4	5,865,787	2 Feb '99	SHAPLAND, J. E. et al.			
5	5,387,419	7 Feb '95	LEVY, R. J.			
6	5,286,254	15 Feb '94	SHAPLAND, J. E. et al.			
7	5,458,568	17 Oct '95	RACCHINI, J. R. et al.			
8	5,282,785	1 Feb '94	SHAPLAND, J. E. et al.			
9	5,236,413	17 Aug '93	FEIRING, A. J.			
10	6,298,268	2 Oct '01	BEN-HAIM, S. et al.			
11	5,419,763	30 May '95	HILDEBRAND, K. R.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
12	WO 98/15317	16 Apr '98	PCT				
13	WO 97/25098	17 Jul '97	PCT				
14	WO 00/16741	30 Mar '00	PCT				
15	WO 99/03533	28 Jan '99	PCT				
16	WO 00/53257	14 Sep '00	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

17	PATTERSON, C. et al.; "Therapeutic Angiogenesis - The New Electrophysiology?;" May 25, 1999; pp. 2614-2616; Circulation; 1999 American Heart Association, Inc.
18	TSONG, T. Y.; "Electroporation of Cell Membranes;" August 1991; pp. 297-306; Biophysical Journal; Vol. 60

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APR 22 2002

ATTY DOCKET NO.

015/02481

SERIAL NO.

09/980,908

Nissim DARVISH, et al.

FILING

December 4, 2001

GROUP

3763

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	19	5,499,971	19 Mar '96	SHAPLAND, J. E. et al.			
	20	5,807,306	15 Sep '98	SHAPLAND, J. E. et al.			
	21	6,292,704	18 Sep '01	MALONEK, D. et al.			
	22	5,415,629	16 May '95	HENLEY, J. L.			
	23	5,779,661	14 Jul '98	STEPHEN, R. L. et al.			
	24	6,086,582	11 Jul '00	ALTMAN, P. A. et al.			
	25	5,386,837	7 Feb '95	STERZER, F.			
	26	5,327,887	12 Jul '94	NOWAKOWSKI, L.			
	27	4,273,114	16 Jun '81	BARKALOW, C. E. et al.			
	28	4,164,216	14 Aug '79	PERSON, O. W.			
	29	6,071,305	6 Jun '00	BROWN, J. E. et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	30	WO 99/24110	20 May '99	PCT				
	31	WO 99/59548	25 Nov '99	PCT				
	32	WO 99/29307	17 Jun '99	PCT				
	33	WO 95/08316	30 Mar '95	PCT				
	34	WO 92/00716	23 Jan '92	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	35	SUKHORUKOV, V. L. et al.; "The Effect of Electrical Deformation Forces on the Electroporabilization of Erythrocyte Membranes in Low- and High-Conductivity Media;" 1998; pp. 235-245; The Journal of Membrane Biology; Vol. 163
	36	GUSSONL, E. et al.; "Dystrophin Expression in the MDX Mouse Restored by Stem Cell Transplantation;" 23 September 1999; pp. 390-394; Nature; Vol. 401; No. 6751

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY DOCKET NO.

015/02481

SERIAL NO.

09/980,908

Nissim DARVISH, et al.

FILING

December 4, 2001

GROUP

3763

APR 22 2002

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
37	6,057,374	2 May '00	HUNTINGTON, J. A. et al.			
38	6,041,252	21 Mar '00	WALKER, J. P. et al.			

RECEIVED

APR 25 2002

TECHNOLOGY CENTER

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
39	WO 99/55360	4 Nov '99	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

40	CANO, N. J. et al.; "Dose-Dependent Reversal of Digoxin-Inhibited Activity of an In-Vitro Na+K+ATPase Model by Digoxin-Specific Antibody;" May 1996; pp. 107-1011; Toxicology Letters;; Vol. 85; No. 2
41	MORAN, R. J. et al.; "Digoxin-Specific Fab Fragments Impair Renal Function in the Rat;" 1994; pp. 854-856; Journal of Pharmacy and Pharmacology; Vol. 46; No. 10

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Use several sheets if necessary)

APR 22 2002

SERIAL NO. 09/980,908

Nissim DARVISH, et al.

FILING
December 4, 2001

GROUP	3763
-------	------

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	42	ANTMAN, E. M. et al.; "Treatment of 150 Cases of Life-Threatening Digitalis Intoxication with Digoxin-Specific Fab Antibody Fragments;" June 1990;Circulation; Vol. 81; No. 6; pp. 1744-1752
	43	SHUMAIK, G. M. et al; "Oleander Poisoning: Treatment with Digoxin-Specific Fab Antibody Fragments;" July 1988; pp. 732-735; Annals of Emergency Medicine; Vol. 17; No. 7

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.